Shenkang injection for the treatment of acute kidney injury: a systematic review and meta-analysis
CONCLUSION: The use of SKI in AKI patients may reduce SCr, BUN, CysC, 24-h Upro levels, and APACHE II scores in AKI patients. The incidence of adverse reactions did not differ from that in the control group. Additional rigorous clinical trials will be necessary in the future to thoroughly evaluate and establish the effectiveness of SKI in the treatment of AKI.PMID:38655870 | PMC:PMC11044765 | DOI:10.1080/0886022X.2024.2338566
Source: Renal Failure - Category: Urology & Nephrology Authors: Shengchun Liao Yurou Chen Shuting Wang Chen Wang Chaoyang Ye Source Type: research
More News: China Health | Clinical Trials | Databases & Libraries | Renal Failure | Study | Urology & Nephrology